Devomycin D Solution For Injection
Revised: April 2011
Amended pages
SUMMARY OF PRODUCT CHARACTERISTICS
1. Name of the veterinary medicinal product
Devomycin D Solution for Injection.
2. Qualitative and quantitative composition
Active Substance:
Each ml contains:
Streptomycin Sulfate 150 mg
Dihydrostreptomycin Sulfate 150 mg.
Excipients:
Chlorocresol 1mg
Sodium Metabisulphate 1mg
For a full list of excipients, see section 6.1
3. Pharmaceutical form
Solution for Injection
A clear pale yellow solution for Injection.
4. Clinical Particulars
4.1 Target species
Horses
Cattle
Sheep
Dogs
Cats
4.2 Indications for use, specifying the target species
Devomycin D Injection is active against a wide range of Gram-negative organisms and some Gram-positive pathogens. It is indicated in the treatment of organisms sensitive to Streptomycin. Among the more sensitive to streptomycin in vitro are Actinobacillus equuli, A. lignieresii, Actinomyces bovis, Brucella spp, E. coli, Haemophilus spp, Klebsiella spp, Leptospira canicola and L. ictero-haemorrhagiae, Pseudomonas aeruginosa and some species of Proteus, Pasteurella and Salmonella.
4.3 Contraindications
Contraindicated in cases of known hypersensitivity to the active ingredients.
4.4 Special Warnings for each target species
No special warnings.
4.5 Special precautions for use
Special precautions for use in animals
Use of the product should be based on susceptibility testing of bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.
Take particular care when treating animals suffering from renal damage.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Do not handle this product if you are sensitised (allergic) to aminoglycoside antibiotics.
Care should be taken to avoid accidental self-injection. In case of accidental injection seek medical advice.
In case of accidental contact with skin or eyes, wash the affected area with plenty of water immediately.
Wash hands after use.
4.6 Adverse reactions (frequency and seriousness)
None.
4.7 Use during pregnancy, lactation or lay
Devomycin D Injection can be safely administered during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interaction
Concurrent use with other potentially nephrotoxic drugs, such as diuretics, should be avoided.
4.9 Amounts to be administered and administration route
For intramuscular injection only.
Horses, cattle and sheep: 10 mg active ingredients/kg bodyweight daily (1 ml/30 kg bodyweight) for a maximum of 3 days.
Dogs and cats: 25 mg active ingredients/kg bodyweight daily (1 ml/12 kg bodyweight) for a maximum of 3 days.
Care should be taken in computing the dose to avoid overdosage.
To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.
Do not inject more than 10ml of this product into any one injection site. Failure to heed this warning may lead to residues above the legal limit in food for human consumption.
Overdose (symptoms, emergency procedures, antidotes), if necessary
Excessive and prolonged administration can lead to interference with balance and hearing. In extreme cases the damage can be permanent. Cats are the most susceptible animals.
Withdrawal period
Cattle (Meat & Offal): 14 days
Cattle (Milk): 48 hours
Sheep (Meat & Offal): 14 days
Sheep (Milk): Do not use in sheep producing milk intended for human consumption.
Horses: Not to be used in horse intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.
5. pharmacological properties
Pharmacotherapeutic group: Antibacterials for systemic use, Aminoglycoside antibacterials, Streptomycins
ATC Vet Codes: QJ01GA01 & QJ01GA90
Pharmacodynamic properties
Streptomycin is a member of the amino glycosides group of antibiotics and is thought to act by entering the bacterial cell and combining irreversibly with ribosomal RNA. This combination interferes with protein synthesis including misreading of the amino-acid sequence and premature termination of the protein chain, resulting in the death of the bacteria.
6. Pharmaceutical particulars
6.1 List of excipients
Chlorocresol
Sodium Metabisulphate
Sodium Citrate Anhydrous
Citric acid, Anhydrous (for pH adjustment)
Water for Injections
Incompatibilities
None Known
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 Years.
Shelf life after first opening the immediate packaging: 28 Days.
Special precautions for storage
Do not store above 25ÂșC.
Protect from light.
Following withdrawal of the first dose, use the product within 28 days.
Discard unused material.
Nature and composition of immediate packaging
100ml sterile, amber, type II glass siliconised, multi-dose vials closed with grey rubber plug septum secured by a aluminium tamper evident crimped seal.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused product or waste material should be disposed of in accordance with national requirements.
7. MARKETING AUTHORISATION HOLDER
Norbrook Laboratories Limited
Station Works
Newry
Co. Down, BT35 6JP
Northern Ireland
8. MARKETING AUTHORISATION NUMBER
Vm 02000/4034
9. DATE OF RENEWAL OF AUTHORISATION
Date: 24 October 2010
10. DATE OF REVISION OF THE TEXT
Date: April 2011
4